{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:28Z","timestamp":1786986928402,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clineuro.2025.108910","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:56:09Z","timestamp":1745466969000},"page":"108910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta\u2011analysis"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3579-9141","authenticated-orcid":false,"given":"Muzamil","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmood","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzala Ahmed","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Maryam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Muzammil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummara","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Athar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarak","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2025.108910_bib1","series-title":"Immunological Medicine","first-page":"1","article-title":"Pathogenesis and detection methods of anti-acetylcholine receptor antibodies in myasthenia gravis","author":"Suzuki","year":"2025"},{"key":"10.1016\/j.clineuro.2025.108910_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clineuro.2025.108910_bib3","series-title":"Neuroepidemiology","first-page":"1","article-title":"Prevalence, incidence, and mortality of myasthenia gravis and myasthenic syndromes: a systematic review","author":"Sciancalepore","year":"2024"},{"key":"10.1016\/j.clineuro.2025.108910_bib4","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.108910_bib5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1186\/s12967-024-05751-1","article-title":"Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis","volume":"22","author":"Gu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.clineuro.2025.108910_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.clineuro.2025.108910_bib7","first-page":"114","article-title":"International consensus guidance for management of myasthenia gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurol. [Internet]"},{"key":"10.1016\/j.clineuro.2025.108910_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.790834","article-title":"Different monoclonal antibodies in myasthenia gravis: a bayesian network meta-analysis","volume":"12","author":"Song","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.clineuro.2025.108910_bib9","first-page":"1637","article-title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"12","key":"10.1016\/j.clineuro.2025.108910_bib10","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Sacc\u00e0","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.clineuro.2025.108910_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.clineuro.2025.108910_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(24)00514-3","article-title":"Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"24","author":"Habib","year":"2025","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.clineuro.2025.108910_bib13","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","article-title":"The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis","volume":"271","author":"Li","year":"2024","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.108910_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/nyas.13503","article-title":"The Association of British Neurologists' myasthenia gravis guidelines","volume":"1412","author":"Sussman","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.clineuro.2025.108910_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2025.108910_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000241","article-title":"New and emerging treatments for myasthenia gravis","volume":"2","author":"DeHart-McCoyle","year":"2023","journal-title":"BMJ Med."},{"key":"10.1016\/j.clineuro.2025.108910_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/10600280241239048","article-title":"Rozanolixizumab: a new therapy in the treatment of Myasthenia gravis","author":"Hitt","year":"2024","journal-title":"Ann. Pharmacother."},{"issue":"5","key":"10.1016\/j.clineuro.2025.108910_bib18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"issue":"14","key":"10.1016\/j.clineuro.2025.108910_bib19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","article-title":"Rozanolixizumab: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.clineuro.2025.108910_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2217\/imt-2022-0298","article-title":"Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis","volume":"15","author":"Sivadasan","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clineuro.2025.108910_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","article-title":"Efgartigimod alfa in generalised Myasthenia gravis: a profile of its use","volume":"37","author":"Heo","year":"2023","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.clineuro.2025.108910_bib22","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized Phase 2 Vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2025.108910_bib23","article-title":"Subcutaneous batoclimab in generalized myasthenia gravis: results from a Phase 2a trial with an open-label extension","author":"Nowak","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.clineuro.2025.108910_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic effects of batoclimab in Chinese patients with generalized Myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.clineuro.2025.108910_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurol.2024.09.006","article-title":"New treatment strategies in myasthenia gravis","author":"Attarian","year":"2024","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.clineuro.2025.108910_bib26","article-title":"Advances and challenges in the treatment of myasthenia gravis","volume":"15","author":"Schneider-Gold","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2025.108910_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.clineuro.2025.108910_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1474884","article-title":"Application of digital tools and artificial intelligence in the Myasthenia gravis core examination","volume":"15","author":"Garbey","year":"2024","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.108910_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000531224","article-title":"Development and assessment of an artificial intelligence-based tool for ptosis measurement in adult myasthenia gravis patients using selfie video clips recorded on smartphones","volume":"7","author":"Lootus","year":"2023","journal-title":"Digit. Biomark."},{"issue":"9","key":"10.1016\/j.clineuro.2025.108910_bib30","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/bioengineering11090942","article-title":"AI-powered telemedicine for automatic scoring of neuromuscular examinations","volume":"11","author":"Lesport","year":"2024","journal-title":"Bioengineering"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725001933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725001933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T10:14:31Z","timestamp":1747995271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846725001933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"alternative-id":["S0303846725001933"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.108910","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta\u2011analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.108910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108910"}}